2-(sec-butyl)furan | 28752-87-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 2-(sec-butyl)furan
• 英文别名: 2-s-butylfuran；2-sec-butyl-furan；2-sec-Butylfuran；2-butan-2-ylfuran
• CAS: 28752-87-6
• 化学式: C₈H₁₂O
• 分子量: 124.183
• InChiKey: FITPKMAKSVCPDP-UHFFFAOYSA-N

物化性质

• 沸点：
  132-135 °C
• 密度：
  0.894±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  13.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(sec-butyl)furan 、 邻氨基苯甲酸 在 亚硝酸异戊酯 作用下， 以 四氢呋喃 为溶剂， 反应 3.33h， 以29%的产率得到1-s-butyloxabenzonorbornadiene
  参考文献：
  名称：

  Synthesis of C1-Substituted Oxabenzonorbornadienes

  摘要：

  Oxabenzonorbornadienes are valuable synthetic intermediates because they can serve as a general template with which to create highly substituted ring systems. However, to date, only very few C1-substituted oxabenzonorbornadienes have been reported. In this study, the synthesis of some C1-substituted oxabenzonorbornadienes was achieved by the Diels-Alder reaction between 2-substituted furans and benzyne. Moderate to good yields (16-80%) of the Diels-Alder reactions were observed. These C1-substituted oxabenzonorbornadienes will find applications as valuable synthetic intermediates and should be useful in studies of transition-metal-catalyzed reactions.

  DOI：

  10.1055/s-0032-1316686
• 作为产物：
  描述：

  (3-butan-2-yl-4,5-dihydro-1,2-oxazol-5-yl)methyl acetate 生成 2-(sec-butyl)furan
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20160031830A1

  公开（公告）日：2016-02-04

  Substituted dihydropyrimidinones of formula 1 which are neutrophil elastase inhibitors and useful as medicaments for the treatment of, inter alia, COPD. Exemplary is

  式1的替代二氢嘧啶酮是中性粒细胞弹性蛋白酶抑制剂，可用作治疗COPD等疾病的药物。
• Synthesis of 2-Substituted Furans by Iron- and Palladium-Catalyzed Coupling Reactions
  作者：William Tam、Jamie Haner、Kelsey Jack、Jaipal Nagireddy、Mohammed Raheem、Robin Durham

  DOI：10.1055/s-0030-1259484

  日期：2011.3

  synthesis of 2-substituted furans via palladium- and iron-catalyzed coupling utilizing 2-bromofuran is described. Whereas palladium-catalyzed Suzuki coupling effectively provided the corresponding aryl furans, little or no product was obtained by palladium-catalyzed coupling with various alkyl nucleophiles. Iron-catalyzed coupling proved effective for the synthesis of primary and secondary alkyl furans in modest

  描述了利用2-溴呋喃通过钯和铁催化的偶联来合成2-取代的呋喃。尽管钯催化的Suzuki偶联有效地提供了相应的芳基呋喃，但是通过钯催化的与各种烷基亲核试剂的偶联得到的产物很少或没有。铁催化的偶合被证明对于以中等收率合成伯和仲烷基呋喃以及以低收率合成芳基呋喃是有效的。 呋喃-交叉偶联-催化-钯-铁
• Analogs of dehydrophenylahistins and their therapeutic use
  申请人：Palladino Michael

  公开号：US20070078138A1

  公开（公告）日：2007-04-05

  Compounds represented by the following structure (II) are disclosed: as are methods for making such compounds. Compositions and methods for treating various disease conditions including cancer and non-cancer diseases associated with vascular proliferation are also disclosed.

  本文揭示了由以下结构（II）所代表的化合物，以及制造这种化合物的方法。此外，还揭示了用于治疗各种疾病状况的组合物和方法，包括与血管增殖有关的癌症和非癌症疾病。
• Thiadiazole modulators of PKB
  申请人：Zeng Qingping

  公开号：US20090298836A1

  公开（公告）日：2009-12-03

  The invention relates to thiazole compounds of Formula I and Formula II and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

  本发明涉及一种化合物，其为公式I和公式II的噻唑化合物，以及其组合物，可用于治疗由蛋白激酶B（PKB）介导的疾病，其中变量具有本文中提供的定义。本发明还涉及在治疗异常细胞生长、癌症、炎症和代谢紊乱等疾病状态中使用这种噻唑化合物和其组合物的治疗用途。
• Inhibitors of Protein Tyrosine Kinase Activity
  申请人：Mannion Michael

  公开号：US20110098293A1

  公开（公告）日：2011-04-28

  This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.

  本发明涉及抑制蛋白酪氨酸激酶活性的化合物。特别是，本发明涉及抑制生长因子受体的蛋白酪氨酸激酶活性的化合物，从而抑制受体信号传导，例如抑制VEGF受体信号传导。本发明还提供了用于治疗细胞增殖性疾病和状况以及眼科疾病、异常和状况的化合物、组合物和方法。